Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 264


Effect of highly active antiretroviral therapy on time to acquired immunodeficiency syndrome or death using marginal structural models.

Cole SR, Hernán MA, Robins JM, Anastos K, Chmiel J, Detels R, Ervin C, Feldman J, Greenblatt R, Kingsley L, Lai S, Young M, Cohen M, Muñoz A.

Am J Epidemiol. 2003 Oct 1;158(7):687-94.


Marginal structural models for estimating the effect of highly active antiretroviral therapy initiation on CD4 cell count.

Cole SR, Hernán MA, Margolick JB, Cohen MH, Robins JM.

Am J Epidemiol. 2005 Sep 1;162(5):471-8. Epub 2005 Aug 2.


[Marginal structural models application to estimate the effects of antiretroviral therapy in 5 cohorts of HIV seroconverters].

Pérez-Hoyos S, Ferreros I, Hernán MA; GEMES.

Gac Sanit. 2007 Jan-Feb;21(1):76-83. Spanish.


Using marginal structural measurement-error models to estimate the long-term effect of antiretroviral therapy on incident AIDS or death.

Cole SR, Jacobson LP, Tien PC, Kingsley L, Chmiel JS, Anastos K.

Am J Epidemiol. 2010 Jan 1;171(1):113-22. doi: 10.1093/aje/kwp329. Epub 2009 Nov 24.


Long-term effectiveness of highly active antiretroviral therapy on the survival of children and adolescents with HIV infection: a 10-year follow-up study.

Patel K, Hernán MA, Williams PL, Seeger JD, McIntosh K, Van Dyke RB, Seage GR 3rd; Pediatric AIDS Clinical Trials Group 219/219C Study Team.

Clin Infect Dis. 2008 Feb 15;46(4):507-15. doi: 10.1086/526524.


The prognostic importance of changes in CD4+ cell count and HIV-1 RNA level in women after initiating highly active antiretroviral therapy.

Anastos K, Barrón Y, Cohen MH, Greenblatt RM, Minkoff H, Levine A, Young M, Gange SJ.

Ann Intern Med. 2004 Feb 17;140(4):256-64.


Marginal structural models to estimate the causal effect of zidovudine on the survival of HIV-positive men.

Hernán MA, Brumback B, Robins JM.

Epidemiology. 2000 Sep;11(5):561-70.


Risk of progression to AIDS and death in women infected with HIV-1 initiating highly active antiretroviral treatment at different stages of disease.

Anastos K, Barrón Y, Miotti P, Weiser B, Young M, Hessol N, Greenblatt RM, Cohen M, Augenbraun M, Levine A, Muñoz A; Women's Interagency HIV Study Collaborative Study Group.

Arch Intern Med. 2002 Sep 23;162(17):1973-80.


Structural accelerated failure time models for survival analysis in studies with time-varying treatments.

Hernán MA, Cole SR, Margolick J, Cohen M, Robins JM.

Pharmacoepidemiol Drug Saf. 2005 Jul;14(7):477-91.


Pregnancy and HIV disease progression during the era of highly active antiretroviral therapy.

Tai JH, Udoji MA, Barkanic G, Byrne DW, Rebeiro PF, Byram BR, Kheshti A, Carter JD, Graves CR, Raffanti SP, Sterling TR.

J Infect Dis. 2007 Oct 1;196(7):1044-52. Epub 2007 Aug 29.


Effect of discontinuing antiretroviral therapy on survival of women initiated on highly active antiretroviral therapy.

Barrón Y, Cole SR, Greenblatt RM, Cohen MH, Anastos K, DeHovitz JA, Delapenha R, Gange SJ.

AIDS. 2004 Jul 23;18(11):1579-84.


Effect of tuberculosis on the survival of women infected with human immunodeficiency virus.

López-Gatell H, Cole SR, Hessol NA, French AL, Greenblatt RM, Landesman S, Preston-Martin S, Anastos K.

Am J Epidemiol. 2007 May 15;165(10):1134-42. Epub 2007 Mar 5.


Mortality in HIV-seropositive versus -seronegative persons in the era of highly active antiretroviral therapy: implications for when to initiate therapy.

Wang C, Vlahov D, Galai N, Bareta J, Strathdee SA, Nelson KE, Sterling TR.

J Infect Dis. 2004 Sep 15;190(6):1046-54. Epub 2004 Aug 17.


Mortality and progression to AIDS after starting highly active antiretroviral therapy.

van Sighem AI, van de Wiel MA, Ghani AC, Jambroes M, Reiss P, Gyssens IC, Brinkman K, Lange JM, de Wolf F; ATHENA Cohort Study Group.

AIDS. 2003 Oct 17;17(15):2227-36.


Uniform risk of clinical progression despite differences in utilization of highly active antiretroviral therapy: Swiss HIV Cohort Study.

Junghans C, Low N, Chan P, Witschi A, Vernazza P, Egger M.

AIDS. 1999 Dec 24;13(18):2547-54.


Determinants of clinical progression in antiretroviral-naive HIV-infected patients starting highly active antiretroviral therapy. Aquitaine Cohort, France, 1996-2002.

Bonnet F, Thiébaut R, Chêne G, Neau D, Pellegrin JL, Mercié P, Beylot J, Dabis F, Salamon R, Morlat P; Groupe d'Epidemiologie Clinique du SIDA en Aquitaine (GECSA).

HIV Med. 2005 May;6(3):198-205.


[Survival, progression to AIDS and immunosuppression in HIV-positive individuals before and after the introduction of the highly active antiretroviral therapy (HAART)].

Pezzotti P, Dorrucci M, Donisi A, Cusini M, Mazzarello G, De Luca A, Salassa B, Ursitti MA, Giuliani M, Rezza G; l'Italian Seroconversion Study.

Epidemiol Prev. 2003 Nov-Dec;27(6):348-55. Italian.

Items per page

Supplemental Content

Write to the Help Desk